X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration combines the drug discovery, clinical development and data science expertise from Johnson with BigHat’s Milliner™ platform to guide the design and selection for high-quality antibodies for multiple Neuroscience therapeutic targets.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 24, 2024
Details:
The collaboration aims to discover and develop next-generation therapeutic antibodies in oncology and neuroscience by utilising BigHat's Milliner™ platform, a suite of machine learning technologies integrated with a high-speed wet lab.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $355.0 million Upfront Cash: $30.0 million
Deal Type: Collaboration December 05, 2023
Details:
Achievement of this first milestone shows that BigHat’s platform has the potential to effectively and efficiently design high-quality therapeutic antibodies. This triggers the initiation of work to create a lead panel of VHH antibodies for patients in need.
Lead Product(s): Antibody
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 11, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
